哪些患者可能尤其适合基于奥美沙坦的联合治疗？
Which patients might be particularly suitable for olmesartan-based combination therapy?
通过优化反应条件抑制异构体的量，从而保证奥美沙坦酯的质量。
Optimization of the condensation conditions reduced the impurity to a negligible quantity.
显然，在全部药物中，奥美沙坦在控制血压方面有非常重要的地位。
It is clear that olmesartan has a very good position in the armamentarium to control blood pressure.
与单用奥美沙坦或利尿剂相比，奥美沙坦与利尿剂联合有更强的降压效应。
The combination of olmesartan with a diuretic has a stronger effect on BP lowering compared to olmesartan or diuretic alone.
这是奥美沙坦的完全反向激动效应，也是其成为最强效arb的潜在机制。
I think this is the effect of olmesartan complete reverse agonism and also underlying mechanism of olmesartan makes it the strongest ARB.
这意味着与安慰剂组相比，奥美沙坦组出现微量白蛋白尿的风险降低了23%。
This translated into a risk reduction of 23% for the olmesartan group, compared with the placebo group.
但之后统计的数据均提示，奥美沙坦组出现微量白蛋白尿的患者少于安慰剂组。
For the remainder of the study, fewer patients in the olmesartan group experienced microalbuminuria, compared with patients in the placebo group.
对于老年或非裔美国的一期高血压患者，他推荐奥美沙坦合用利尿药或钙拮抗剂。
For elderly or African-American patients with stage 1 hypertension, he recommended initial monotherapy with a diuretic or calcium antagonist.
值得注意的是在有冠心病史的患者中，奥美沙坦引起的致死性心血管事件发生率较高。
The higher rate of fatal cardiovascular events with olmesartan among patients with preexisting coronary heart disease is of concern.
我认为这是治疗高血压的最佳组合，因为奥美沙坦和氨氯地平均有着极强的降压作用。
I think this is the best combination for treatment of hypertension since olmesartan and amlodipine have very potent blood pressure lowering effects.
最重要的是，奥美沙坦使夜间血压降低较多，且在两次服药中间的最后4小时内亦然。
The most important thing is that at night the reduction of blood pressure was higher and also during the last four hours of the interdose period.
另外，来自ROADMAP研究的数据证明，在T2DM患者中奥美沙坦可降低MAU风险。
In addition, data from the ROADMAP study proved that olmesartan can reduce risk of MAU in T2DM patients.
根据这些发现，我们是否可以得出结论，即奥美沙坦治疗可以带来显著降低CVD风险的获益？
According to these findings can we conclude that treatment with olmesartan will bring us more promising benefits in reducing CVD risk?
此外，ROADMAP数据证明奥美沙坦可预防2型糖尿病患者发生微量白蛋白尿(mau)。
In addition, data from ROADMAP proved that olmesartan can reduce risk of microalbuminuria (MAU) in Type 2 diabetes (T2DM) patients.
另外，已有奥美沙坦与利尿剂HCTZ以及CCB氨氯地平的联合药物，是非常强效的降压药物。
In addition, combinations of olmesartan with the diuretic HCTZ and also the CCB amlodipine are also available and are very powerful blood pressure reducing agents.
结论：奥美沙坦与微量蛋白尿延缓出现有关，尽管基于现行标准，两组患者的血压控制情况均较好。
CONCLUSIONS: Olmesartan was associated with a delayed onset of microalbuminuria, even though blood-pressure control in both groups was excellent according to current standards.
根据这些结果，我们能否得出以下结论，即奥美沙坦治疗对于降低CVD风险将带来更有前景的益处？
According to these findings, can we conclude that treatment with olmesartan will bring more promising benefits in reducing CVD risk?
HermannHaller教授：过去几年中，奥美沙坦已被证明有某些令人感兴趣的器官保护特征。
Prof Hermann Haller: Olmesartan has been shown over the last couple of years to have some interesting features for organ protection.
奥美沙坦组没有出现任何累及肾脏转归的不良事件。总的来看，心血管疾病的发病率和病死率很低，不足整个受试人群的1%。
No adverse events from olmesartan were observed on renal outcomes, and the incidence of cardiovascular morbidity and mortality was low overall, affecting fewer than 1% of the entire study population.
奥美沙坦组没有出现任何累及肾脏转归的不良事件。总的来看，心血管疾病的发病率和病死率很低，不足整个受试人群的1%。
No adverse events from olmesartan were observed on renal outcomes, and the incidence of cardiovascular morbidity and mortality was low overall, affecting fewer than 1% of the entire study population.
应用推荐